
Abraham S Kanate

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4155184/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of antiâ€anaerobic antibiotic activity on graftâ€versusâ€host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling. Transplant Infectious Disease, 2021, 23, e13676.	1.7	1
2	Prospective assessment of <i>Clostridioides</i> (formerly <i>Clostridium</i>) <i>difficile</i> colonization and acquisition in hematopoietic stem cell transplant patients. Transplant Infectious Disease, 2020, 22, e13438.	1.7	1
3	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	7.2	27
4	Single versus doubleâ€unit transfusion: Safety and efficacy for patients with hematologic malignancies. European Journal of Haematology, 2019, 102, 383-388.	2.2	8
5	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1859-1868.	2.0	58
6	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
7	Delayed-onset effect of clofarabine in the treatment of an adult patient with acute myeloid leukemia. American Journal of Health-System Pharmacy, 2019, 76, 349-352.	1.0	Ο
8	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 683-688.	2.0	18
9	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer, 2018, 124, 2541-2551.	4.1	61
10	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€cell lymphoma, nasal type: a <scp>CIBMTR</scp> analysis. British Journal of Haematology, 2018, 182, 916-920.	2.5	59
11	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	5.2	35
12	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11
13	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2017, 23, 853-856.	2.0	28
14	Treatment of severe mucositis pain with oral ketamine mouthwash. Supportive Care in Cancer, 2017, 25, 2215-2219.	2.2	23
15	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1295-1302.	2.0	8
16	Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Leukemia Research and Treatment, 2017, 2017, 1-6.	2.0	16
17	Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia. Advances in Hematology, 2017, 2017, 1-4.	1.0	5
18	Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Management and Research, 2017, Volume 9, 307-314.	1.9	25

Abraham S Kanate

#	Article	IF	CITATIONS
19	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood, 2016, 127, 938-947.	1.4	246
20	Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. Supportive Care in Cancer, 2016, 24, 4237-4240.	2.2	5
21	Impact of Pretransplantation 18F-fluorodeoxy Clucose–Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 1605-1611.	2.0	39
22	Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrobial Agents and Chemotherapy, 2015, 59, 4424-4428.	3.2	60
23	Hematopoietic progenitor cell mobilization with "just-in-time―plerixafor approach is a cost-effective alternative to routine plerixafor use. Cytotherapy, 2015, 17, 1785-1792.	0.7	30
24	Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 415-420.	2.0	16
25	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World Journal of Stem Cells, 2014, 6, 69.	2.8	29
26	Salvage Bone Marrow Harvest in Patients Failing Plerixafor-Based Stem Cell Mobilization Attempt: Feasibility and Autologous Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2013, 19, 1133-1135.	2.0	5
27	Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma. Bone Marrow Research, 2012, 2012, 1-11.	1.7	2